483 Roundup: FDA Cites Eight Firms for Quality Issues Post author:Sam Post published:May 5, 2020 Post category:Drug GMP Report The FDA found a range of quality lapses during inspections at eight U.S.-based plants. Source: Drug GMP Report You Might Also Like EMA Updates Guidelines for Postmarket Studies and Variations August 7, 2017 Expert Lists Data Integrity Red Flags for Drug Sponsors October 3, 2017 FDA Warns Bangalore Drugmaker for Contamination Investigations September 10, 2020